CEO Comments

AN EXCITING TIME AHEAD During the year, major changes have been made in the company’s two business areas; in Chromatography, Nanologica now focuses mainly on preparative chromatography, and in Drug Development the strategy has been refined to focus on inhaled drugs and respiratory diseases. This has been done to create the best possible growth conditions and value development going forward, for each business area as well as for the company as a whole. In line

FOCUS ON PRODUCTION! Net sales for the quarter increased marginally to TSEK 2,119, most of which again is derived from our partner project with Vicore Pharma. The quarter’s increased operating loss compared to the previous year is according to plan and is mainly due to the expansion phase in which the company is currently in. To take the next step in our growth, we are now fully focused on completing large-scale production capacity, which is

LARGE-SCALE PRODUCTION AND TOXICITY STUDIES Production of the company’s silica for preparative chromatography in large scale proceeds according to plan. Commercial material is expected to be delivered at the end of the year, after which the company can start delivering on customer agreements. At the same time, we continue to strengthen our platform in inhalation and respiratory diseases with a comprehensive tox program and increased resources for development and commercialization. Net sales for the second

IMPORTANT MILESTONES ACHIEVED IN BOTH BUSINESS AREAS Successful upscaling of the production of silica to ton scale advances Nanologica’s position in the preparative chromatography field. At the same time, the company’s platform for inhalation advances through a toxicology program, with eyes set on clinical studies. Sales for the first quarter amounted to TSEK 5,622, where the majority is derived from our partner project with Vicore Pharma. This is our strongest first quarter yet and we

STRONG PERFORMANCE AND INVESTMENTS FOR THE FUTURE 2020 has been a challenging year, but it is with both delight and pride I can look back on the year and the progress we have made within both our business areas. Nanologica’s strong growth continued and we reached record net sales for the Company so far, at the same time as we made large investments to be able to create value over time. We passed a large